Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Abrau-Durso plans to open a wine tourism center in Azerbaijan

5/12/23 ABRD

Alrosa will be headed by the head of a subsidiary of Almazy Anabara

5/12/23 ALRS

Shareholders of TNS Energy Mari El approved dividends for 2022

5/12/23 MISB

EL5-Energo launched the second stage of the Kola Wind Power Plant

5/12/23 ELFV

Abrau-Durso built its first own grape nursery

5/12/23 ABRD

Abrau-Durso plans to double the flow of wine tourists

5/12/23 ABRD

Positive Technologies shareholders approve second part of 2022 dividend

5/12/23 POSI

Fesco has created a route to transport automotive components from China to Belarus

5/12/23 FESH

Aeroflot's passenger traffic in April increased by 55.4%

5/12/23 AFLT

Shareholders of Perm Energy Supply Company approved dividends for 2022

5/12/23 PMSB